Author

L. Eli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. A. Mamun· 1 shared A. B. Hanker· 1 shared A. Marin· 1 shared B. P. Brown· 1 shared C. L. Arteaga· 1 shared d. R. Sudhan· 1 shared D. Ye· 1 shared H. Akamatsu· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Mamun

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancer

A. Marin, A. A. Mamun, H. Akamatsu, D. Ye, d. R. Sudhan, B. P. Brown, L. Eli, K. Marcelain, J. Meiler, C. L. Arteaga, A. B. Hanker

This study identifies secondary HER2 mutations that confer resistance to HER2 kinase inhibitors in HER2-mutant breast cancer by enhancing HER2 signaling and reducing drug binding.

bioRxiv · Sep 23, 2022 · PreprintCancer Biology